Frontotemporal dementia (FTD) — a group of brain diseases that damage the frontal and temporal lobes, changing personality, behavior, and language — currently has no cure and no approved treatment that slows or stops it. It can still be treated in a meaningful but limited sense: doctors can manage symptoms with medication, therapy, and structured support, according to the National Institute on Aging. That distinction matters for planning. Families should expect symptom control and quality-of-life care today, watch the experimental gene-therapy pipeline for tomorrow, and be wary of drugs borrowed from Alzheimer's disease, which do not work in FTD and can make things worse.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What treatment actually looks like today
- Drugs to avoid — and why the wrong prescription is common
- Why FTD is harder to treat than other dementias
- The experimental pipeline — real progress, real setbacks
- What families can practically do now
- Frequently Asked Questions
What treatment actually looks like today
Current care is symptomatic. The National Institute on Aging describes a package built around medications for behavioral symptoms, speech therapy for language variants, occupational and physical therapy to preserve daily function, lifestyle adjustments, safety planning, and support for caregivers. None of these changes the underlying disease, but together they can reduce distress and keep a person functioning longer at home.
For behavioral symptoms — apathy, disinhibition, compulsions, agitation — antidepressants are the first tool. A 2024 European expert consensus published in the European Journal of Neurology recommends low-dose SSRIs as first-line treatment, preferring citalopram or escitalopram and avoiding paroxetine. Stronger drugs are held in reserve. The same consensus reserves antipsychotics such as quetiapine for aggression or self-harm that threatens safety, and advises attempting to taper them within four months rather than leaving patients on them indefinitely.
Drugs to avoid — and why the wrong prescription is common
FTD is often mistaken for Alzheimer's disease, and that misdiagnosis leads directly to the wrong prescription. Cholinesterase inhibitors and memantine — the standard Alzheimer's drugs — show no benefit in FTD and can worsen neuropsychiatric symptoms, so clinicians are advised not to use them, according to a 2025 scoping review of registered FTD trials. The risks go beyond ineffectiveness.
Antipsychotics carry an FDA black-box warning for elderly dementia patients and a considerable risk of movement side effects in FTD. A 2025 database study using TriNetX records linked benzodiazepines, typical antipsychotics, and Alzheimer's drugs to higher hospitalization risk and poorer survival in people with FTD. If a family member with FTD is taking any of these, that is worth a direct conversation with the prescriber:.
- Donepezil, rivastigmine, galantamine, or memantine — Alzheimer's drugs with no FTD benefit
- Typical (older) antipsychotics such as haloperidol
- Benzodiazepines used routinely for agitation
- Paroxetine, the one SSRI the European consensus specifically avoids
Why FTD is harder to treat than other dementias
FTD hits earlier and is more biologically varied than Alzheimer's. It is a leading cause of dementia in people under 60, typically beginning between the 40s and 60s, per the National Institute on Aging — so patients are often still working, raising children, or carrying a mortgage when symptoms start. Genetics splits the disease into two treatment worlds.
A genetic cause — chiefly mutations in the GRN, MAPT, or C9orf72 genes — is found in roughly 15–40% of cases. Because researchers know exactly what those mutations do, gene-targeted therapy has become the main experimental strategy. The flip side: the sporadic majority, with no identified mutation, has no disease-modifying candidate at all. For those patients, the 2025 scoping review notes, care today is limited to symptom management and support.
The experimental pipeline — real progress, real setbacks
The past year showed both faces of FTD research. In October 2025, Alector announced that its Phase 3 trial of latozinemab in FTD patients with GRN mutations failed its clinical co-primary endpoint over 96 weeks — even though the drug raised plasma progranulin 165% versus placebo — and the company ended the program. Raising the deficient protein was not enough to change the disease's course, at least with that approach. Gene therapy remains active.
In March 2026, AviadoBio reported that its ASPIRE-FTD trial of AVB-101, a one-time progranulin gene therapy for FTD-GRN, began enrolling its fourth dose-escalation cohort, with dose-dependent increases in cerebrospinal-fluid progranulin and no related serious adverse events across 20 sites. More data are expected at the AAIC conference in July 2026. The field also narrowed. In May 2026, Passage Bio said it is closing its upliFT-D trial of the gene therapy PBFT02 and enrolling no new patients, per FTD Talk's trial tracking — leaving ASPIRE-FTD and the PROCLAIM gene-replacement study among the remaining FTD-GRN programs.
What families can practically do now
Because every current disease-modifying candidate targets genetic FTD — mostly GRN — genetic testing and counseling are the gateway to trial eligibility. A person with a confirmed GRN mutation may qualify for an active study; someone with sporadic FTD will not, and knowing that early spares false hope and wasted travel.
Practical steps worth taking: Timing matters for trials as much as eligibility. Gene therapies aim to protect brain tissue that still survives, so families pursuing that route should ask about testing at diagnosis rather than waiting for the disease to advance.
- Confirm the diagnosis with a neurologist experienced in FTD, since Alzheimer's misdiagnosis changes the drug plan
- Ask about genetic testing with counseling, especially if any relative had early dementia or ALS
- Review every current medication against the avoid list above
- Start speech, occupational, and physical therapy early, while skills can still be reinforced
- Build safety planning and caregiver support in before a crisis, not after
Frequently Asked Questions
Is FTD ever reversible?
No. Nothing currently reverses or slows the underlying damage; treatment manages symptoms and preserves function for as long as possible, per the National Institute on Aging.
Should someone with FTD take donepezil or memantine?
No. These Alzheimer's drugs show no benefit in FTD, can worsen neuropsychiatric symptoms, and were linked to worse outcomes in a 2025 database study.
Who qualifies for current FTD trials?
Mainly people with a confirmed genetic mutation, mostly in the GRN gene. Genetic testing with counseling is the practical first step toward eligibility.
